FMO5 and atrial fibrillation: The dual effects of sacubitril/valsartan on oxidative stress are mediated by the ability to reduce angiotensin II levels, which in turn suppresses NADPH oxidase activity, a significant source of ROS in the pathogenesis of atrial fibrillation (AF) [52].